FEMY
HEALTHCAREFemasys Inc
Live · NASDAQ · May 9, Close
What's Moving FEMY Today?
No stock-specific AI insight has been generated for FEMY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.45
Fundamentals
Trading
FEMY News
22 articles- Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filedStock Titan·May 9, 2026
- Femasys starts birth-control trial as it expands fertility careStock Titan·May 9, 2026
- Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateYahoo Finance·May 8, 2026
- Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® CompleteYahoo Finance·May 5, 2026
- Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026Yahoo Finance·Apr 22, 2026
- Femasys Drives International Growth with Israeli Market Entry for Fertility PortfolioYahoo Finance·Apr 16, 2026
- Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial GrowthYahoo Finance·Apr 1, 2026
- Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate UpdateYahoo Finance·Mar 31, 2026
- Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of DirectorsYahoo Finance·Mar 18, 2026
- Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial EnrollmentYahoo Finance·Mar 10, 2026
- Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 27, 2026
- Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market AccessYahoo Finance·Feb 26, 2026
- Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal InseminationYahoo Finance·Feb 23, 2026
- Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio ProductsYahoo Finance·Feb 3, 2026
- Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Jan 14, 2026
- Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based CareYahoo Finance·Jan 13, 2026
- Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic DeviceYahoo Finance·Dec 18, 2025
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital DeploymentYahoo Finance·Nov 25, 2025
- Femasys Announces Third Quarter Financial Results for 2025Yahoo Finance·Nov 14, 2025
- Femasys Advances Global Growth with Second Partner Order for FemBloc® in EuropeYahoo Finance·Nov 10, 2025
- BC-Most Active StocksYahoo Finance·Nov 3, 2025
- Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 MillionYahoo Finance·Nov 3, 2025
All 22 articles loaded
Price Data
52-Week Range
$0.45
Fundamentals
Trading
About Femasys Inc
Femasys Inc. is a pioneering medical technology company dedicated to revolutionizing women's healthcare through its advanced proprietary solutions for diagnosing and treating gynecological conditions. The company is noted for its innovative flagship products that provide non-surgical alternatives for prevalent issues such as uterine fibroids and contraception, firmly establishing itself as a leader in the dynamic women's health landscape. As the demand for minimally invasive treatments escalates, Femasys is well-positioned to leverage this trend, delivering enhanced patient outcomes and improving healthcare efficiency. With a strong commitment to addressing substantial unmet needs in women’s health, Femasys seeks to transform the standards of care within this essential sector.